Composition and method for managing blood glucose levels, insulin levels and/or insulin receptor functionality 机翻标题: 暂无翻译,请尝试点击翻译按钮。

公开号/公开日
WO2009026368 A2 2009-02-26 [WO200926368]WO2009026368 A3 2009-12-30 [WO200926368] / 2009-02-262009-12-30
申请号/申请日
2008WO-US73722 / 2008-08-20
发明人
WEBSTER GREGORY D;OPARA EMMANUEL C;
申请人
RESPONSE SCIENTIFIC;
主分类号
IPC分类号
A01N-059/26
摘要
(WO200926368) A combination of constituents for oral administration by women with polycystic ovarian syndrome includes a-lipoic acid, linolenic acid complex, biotin, and coenzyme Q-10.  A preferred method of manufacture is by separate microencapsulation of one or more of the components followed by encapsulation of the individual components, for oral administration.  Other methods of delivery include packaging in impermeable, disposable packets and mixing the formulations with food or a cold liquid.  A combination of constituents for administration by either men or women to encourage increase in brain insulin levels and/or brain insulin receptor functionality also includes a-lipoic acid, linolenic acid complex, biotin, and coenzyme Q-10.
机翻摘要
暂无翻译结果,您可以尝试点击头部的翻译按钮。
地址
代理人
代理机构
;
优先权号
2007US-11843525 2007-08-22 2007US-11855808 2007-09-14
主权利要求
(WO200926368) CLAIMS 1. A composition for oral administration in women for decreasing severity and/or presence of symptoms associated with polycystic ovarian syndrome (PCOS), comprising: α-lipoic acid; linolenic acid complex; biotin; and coenzyme Q-IO. 2. The composition of claim 1 wherein a daily dosage comprises: α-lipoic acid — 100 to 2500 mg.; linolenic acid complex — 10 to 4000 mg.; biotin — 2 to 25 mg.; and coenzyme Q-10 — 25 to 500 mg. 3. The composition of claim 2, wherein the linolenic acid complex includes gamma linolenic acid. 4. A method of managing blood glucose levels, insulin levels and/or insulin receptivity in a woman with polycystic ovarian syndrome (PCOS) and thereby decreasing severity and/or presence of one or more symptom associated with PCOS, comprising ingesting at least once a day an effective amount of four constituents, separately or together in any combination, comprising α-lipoic acid, linolenic acid complex, biotin,. and coenzyme Q-IO. 5. The method of claim 4, wherein a daily dosage of the composition comprises: α-lipoic acid — 100 to 2500 mg.; linolenic acid complex — 10 to 4000 mg.; biotin — 2 to 25 mg.; and coenzyme Q- 10 — 25 to 500 mg. 6. A method of maintaining or improving levels of insulin and/or insulin receptor functionality in the brain, comprising administering to an adult at least the following constituents separately or together: α-lipoic acid, linolenic acid complex, biotin, and coenzyme Q-IO. 7. The method of claim 6, wherein a daily dosage comprises: α-lipoic acid — 100 to 2500 mg.; linolenic acid complex — 10 to 4000 mg.; biotin — 2 to 25 mg.; and coenzyme Q- 10 — 25 to 500 mg. 8. The method of claim 7, wherein the linolenic acid complex includes gamma linolenic acid.
法律状态
(WO200926368) LEGAL DETAILS FOR WO2009026368  Actual or expected expiration date=2011-02-22    Legal state=DEAD    Status=LAPSED     Event publication date=2008-08-20  Event code=WO/APP  Event indicator=Pos  Event type=Examination events  Application details  Application country=WO WOUS2008073722  Application date=2008-08-20  Standardized application number=2008WO-US73722     Event publication date=2009-02-26  Event code=WO/A2  Event type=Examination events  International application published with declaration under Article 17 (2) (a)  Publication country=WO  Publication number=WO2009026368  Publication stage Code=A2  Publication date=2009-02-26  Standardized publication number=WO200926368     Event publication date=2009-12-30  Event code=WO/A3  Event indicator=Pos  Event type=Examination events  Later publication of ISR with revised front page  Publication country=WO  Publication number=WO2009026368  Publication stage Code=A3  Publication date=2009-12-30  Standardized publication number=WO200926368     Event publication date=2011-02-22  Event code=WO/EETL  Event type=Event indicating Not In Force  PCT Application validity period expired. LEGAL DETAILS FOR DESIGNATED STATE DE  Actual or expected expiration date=2010-02-23    Legal state=DEAD    Status=LAPSED   Corresponding cc:  Designated or member state=DE     Event publication date=2010-02-23  Event code=WO/NENP  Event type=Event indicating Not In Force  Non-entry into the national phase in: Corresponding cc:  Designated or member state=DE
专利类型码
A2A3
国别省市代码
若您需要申请原文,请登录。

最新评论

暂无评论。

登录后可以发表评论

意见反馈
返回顶部